Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.

Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307, USA.

BACKGROUND: Bevacizumab has demonstrated activity against a variety of solid tumors, including ovarian carcinoma. However, there have not been reproducible prognostic features associated with its activity. CASES: One patient each with recurrent, refractory well-differentiated serous-endometrioid ovarian carcinoma, micropapillary serous carcinoma of the ovary, and primary peritoneal micropapillary serous carcinoma were treated with single agent bevacizumab (15 mg/m(2) intravenously every 3 weeks). All three have had dramatic sustained responses of 15, 15, and 22 months' duration. CONCLUSION: Bevacizumab may have significant activity against well-differentiated ovarian carcinoma and micropapillary serous carcinomas of the ovary or peritoneum. Since these tumors are generally indolent and not responsive to adjuvant therapy, further investigation is warranted.

Published 16 June 2006 in Gynecol Oncol, 102(1): 5-7.
Full-text of this article is available online (may require subscription).

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.